{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:14:29Z","timestamp":1789791269501,"version":"4.0.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijgc.2025.102859","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:29:41Z","timestamp":1765499381000},"page":"102859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3349-1641","authenticated-orcid":false,"given":"Griffin","family":"Willman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-3043","authenticated-orcid":false,"given":"Vivek","family":"Podder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"Shannon Neville","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-2585","authenticated-orcid":false,"given":"Bradley R.","family":"Corr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":false,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-3096","authenticated-orcid":false,"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102859_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/cancers15041091","article-title":"Management of patients diagnosed with endometrial cancer: comparison of guidelines","volume":"15","author":"Restaino","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/GRF.0b013e318218c6d1","article-title":"Recurrent endometrial cancer","volume":"54","author":"Del","year":"2011","journal-title":"Clin Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102859_bib4","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/ijgc-00009577-200707000-00020","article-title":"Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience","volume":"17","author":"Huh","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102859_bib5","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102859_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102859_bib7","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"23","key":"10.1016\/j.ijgc.2025.102859_bib8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol."},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas","volume":"25","author":"De Jonge","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.ijgc.2025.102859_bib12","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102859_bib13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2025.102859_bib14","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations","volume":"38","author":"Murali","year":"2019","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102859_bib15","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/ERC-15-0237","article-title":"The state-of-play and future of platinum drugs","volume":"22","author":"Apps","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ijgc.2025.102859_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.10.021","article-title":"Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective","volume":"179","author":"Herzog","year":"2023","journal-title":"Eur J Cancer"},{"issue":"suppl 3","key":"10.1016\/j.ijgc.2025.102859_bib17","article-title":"216 An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer","volume":"31","author":"Weichert","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102859_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.32074\/1591-951X-791","article-title":"In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay","volume":"114","author":"Fumagalli","year":"2022","journal-title":"Pathologica"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-82724-w","article-title":"PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition","volume":"14","author":"Pae","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijgc.2025.102859_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2024.01.016","article-title":"Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer","volume":"184","author":"Wehn","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12885-022-09669-z","article-title":"Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort","volume":"22","author":"Leibowitz","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298128","article-title":"Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution","volume":"19","author":"Kang","year":"2024","journal-title":"PLOS One"},{"key":"10.1016\/j.ijgc.2025.102859_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-8258(22)01398-1","article-title":"Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171)","volume":"166","author":"Evans","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102859_bib24","article-title":"Geneva homologous recombination deficiency test is predictive of survival benefit from olaparib and bevacizumab maintenance in ovarian cancer","volume":"9","author":"Christinat","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"48","key":"10.1016\/j.ijgc.2025.102859_bib25","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41388-023-02839-8","article-title":"Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1\/ENGOT-OV25 phase-III trial","volume":"42","author":"Callens","year":"2023","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102859_bib26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.ijgc.2025.102859_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.797","article-title":"735P HRD signature (HRDsig) in endometrial cancer (EC)","volume":"35","author":"Pothuri","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","article-title":"Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs","volume":"3","author":"Marquard","year":"2015","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2018.10.032","article-title":"Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression","volume":"152","author":"Ashley","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102859_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ygyno.2020.12.010","article-title":"Clinical significance of homologous recombination deficiency score testing in endometrial Cancer","volume":"160","author":"Siedel","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102859_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<499::AID-IJC1>3.0.CO;2-T","article-title":"Microsatellite instability in cervical and endometrial carcinomas","volume":"70","author":"Helland","year":"1997","journal-title":"Int J Cancer"},{"issue":"13","key":"10.1016\/j.ijgc.2025.102859_bib33","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.3390\/cancers13133124","article-title":"Mismatch repair deficiency as a predictive and prognostic biomarker in molecularly classified endometrial carcinoma","volume":"13","author":"Loukovaara","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102859_bib34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1200\/JCO.2005.04.1574","article-title":"Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma","volume":"24","author":"Black","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2017.07.003","article-title":"Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival","volume":"146","author":"Cosgrove","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102859_bib36","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/ijgc-2019-000910","article-title":"Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers","volume":"30","author":"Kim","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"29","key":"10.1016\/j.ijgc.2025.102859_bib37","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.ijgc.2025.102859_bib38","article-title":"Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"190","author":"Mirza","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.ijgc.2025.102859_bib39","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.3390\/cancers14163888","article-title":"BRCA mutations in ovarian and prostate cancer: bench to bedside","volume":"14","author":"Boussios","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102859_bib40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102859_bib41","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3390\/jcm11113114","article-title":"Endometrial cancer and BRCA mutations: a systematic review","volume":"11","author":"Gasparri","year":"2022","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.ijgc.2025.102859_bib42","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-21-1104","article-title":"Patients with biallelic BRCA1\/2 inactivation respond to olaparib treatment across histologic tumor types","volume":"27","author":"Van Der Wijngaart","year":"2021","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ijgc.2025.102859_bib43","article-title":"Biallelic BRCA loss and homologous recombination deficiency in nonbreast\/ovarian tumors in germline BRCA1\/2 carriers","volume":"7","author":"Wineland","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102859_bib44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jama.2019.8430","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/MCB.00465-12","article-title":"Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway","volume":"33","author":"Chun","year":"2013","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/cancers13020254","article-title":"Homologous recombination repair mechanisms in serous endometrial cancer","volume":"13","author":"J\u00f6nsson","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib48","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/cancers12030707","article-title":"Changes in DNA damage response markers with treatment in advanced ovarian cancer","volume":"12","author":"Kubelac","year":"2020","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102859_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153032","article-title":"ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer","volume":"216","author":"Sun","year":"2020","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ijgc.2025.102859_bib50","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.ygyno.2024.07.092","volume":"190","author":"Baurain","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102859_bib51","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/OTT.S426923","article-title":"Inhibition of ATM with KU-55933 sensitizes endometrial cancer cell lines to Olaparib","volume":"16","author":"Zhang","year":"2023","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijgo.14969","article-title":"Molecular subtypes of endometrial cancer: implications for adjuvant treatment strategies","volume":"164","author":"Yang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102859_bib53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib54","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41467-020-16416-0","article-title":"Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming","volume":"11","author":"Suryo","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102859_bib55","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/cancers11101458","article-title":"PTEN and gynecological cancers","volume":"11","author":"Nero","year":"2019","journal-title":"Cancers"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2025.102859_bib56","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.33549\/physiolres.935030","article-title":"PTEN mutations as predictive marker for the high-grade endometrial cancer development in Slovak women","volume":"71","author":"Gbelcov\u00e1","year":"2022","journal-title":"Physiol Res"},{"issue":"53","key":"10.1016\/j.ijgc.2025.102859_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001538","article-title":"PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors","volume":"2","author":"Dedes","year":"2010","journal-title":"Sci Transl Med"},{"issue":"6-7","key":"10.1016\/j.ijgc.2025.102859_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1471-2407-14-179","article-title":"Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells","volume":"14","author":"Miyasaka","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib60","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12885-017-3639-0","article-title":"Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors","volume":"17","author":"Philip","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/onc.2017.326","article-title":"PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy","volume":"37","author":"Bian","year":"2018","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102859_bib62","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1158\/1078-0432.CCR-21-1656","article-title":"Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer","volume":"27","author":"Westin","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"8","key":"10.1016\/j.ijgc.2025.102859_bib63","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","article-title":"Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102859_bib65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bjc.6603597","article-title":"Stat3 activation in human endometrial and cervical cancers","volume":"96","author":"Chen","year":"2007","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102859_bib66","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1158\/0008-5472.CAN-14-2498","article-title":"IL6\/JAK1\/STAT3 signaling blockade in endometrial cancer affects the ALDHhi\/CD126+ stem-like component and reduces tumor burden","volume":"75","author":"van der Zee","year":"2015","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-5793(00)02430-3","article-title":"Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells","volume":"488","author":"Gao","year":"2001","journal-title":"FEBS Lett"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102859_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008849","article-title":"STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes","volume":"16","author":"McIntosh","year":"2020","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102859_bib69","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib70","doi-asserted-by":"crossref","first-page":"248","DOI":"10.6004\/jnccn.2014.0025","article-title":"Uterine neoplasms, version 1.2014","volume":"12","author":"Koh","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijgc.2025.102859_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ijgc.2025.102859_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102973","article-title":"PARP and PD-1\/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer","volume":"152","author":"Post","year":"2020","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.ijgc.2025.102859_bib73","doi-asserted-by":"crossref","first-page":"S615","DOI":"10.1016\/j.annonc.2020.08.953","article-title":"814MO phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)","volume":"31","author":"Drew","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102859_bib74","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijgc.2025.102859_bib75","doi-asserted-by":"crossref","first-page":"A17","DOI":"10.1136\/ijgc-2024-ESGO.24","article-title":"407 COPELIA: a 3-arm randomised phase II trial of weekly paclitaxel with or without cediranib or olaparib with cediranib in recurrent endometrial cancer","volume":"34","author":"Clamp","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102859_bib76","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.35151","article-title":"NRG-GY012: randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib\/olaparib in women with recurrent, persistent, or metastatic endometrial cancer","volume":"130","author":"Rimel","year":"2024","journal-title":"Cancer."},{"key":"10.1016\/j.ijgc.2025.102859_bib77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2025.07.008","article-title":"A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer","volume":"200","author":"Corr","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102859_bib78","article-title":"An open label, nonrandomized, multisite phase ii trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer","volume":"40","author":"Bradley","year":"2022","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2022.04.016","article-title":"A phase II trial of bevacizumab and Rucaparib in recurrent carcinoma of the cervix or endometrium","volume":"166","author":"Jackson","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102859_bib80","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib81","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2022.02.025","article-title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","volume":"165","author":"Post","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib82","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-025-56914-7","article-title":"Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced\/metastatic endometrial cancer: the ENDOLA phase I\/II trial","volume":"16","author":"Piffoux","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib83","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1038\/s41467-025-62678-x","article-title":"Maintenance olaparib after platinum-based chemotherapy for advanced\/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial","volume":"16","author":"Joly","year":"2025","journal-title":"Nat Commun"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.102859_bib84","article-title":"Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: results from NRG GY012","volume":"41","author":"Mackay","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib85","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2020.08.003","article-title":"Cost-effectiveness analysis comparing \u201cPARP inhibitors-for-all\u201d to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer","volume":"159","author":"Gonzalez","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.102859_bib86","first-page":"1219","article-title":"Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer","volume":"24","author":"Zhong","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"25","key":"10.1016\/j.ijgc.2025.102859_bib87","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ijgc.2025.102859_bib88","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib89","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41467-023-37084-w","article-title":"Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma","volume":"14","author":"Madariaga","year":"2023","journal-title":"Nat Commun"},{"issue":"suppl 5","key":"10.1016\/j.ijgc.2025.102859_bib90","volume":"9","author":"Van Nieuwenhuysen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijgc.2025.102859_bib91","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2025.04.499","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by durvalumab with\/without olaparib in endometrial cancer: biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation","volume":"200","author":"Moore","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102859_bib92","doi-asserted-by":"crossref","first-page":"A40","DOI":"10.1136\/ijgc-2024-IGCS.47","article-title":"PR005\/# 724 Comprehensive molecular profiling of tumors from a phase II, randomized, double-blind, study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer","volume":"34","author":"Corr","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib93","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"issue":"9737","key":"10.1016\/j.ijgc.2025.102859_bib94","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ijgc.2025.102859_bib95","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102859_bib96","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clbc.2017.12.010","article-title":"BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy","volume":"18","author":"Gornstein","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102859_bib97","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102859_bib98","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2017.40","article-title":"BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","volume":"116","author":"Pishvaian","year":"2017","journal-title":"Br J Cancer"},{"issue":"7182","key":"10.1016\/j.ijgc.2025.102859_bib99","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102859_bib100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib101","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib102","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor Rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102859_bib103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:20:35Z","timestamp":1780003235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1048891X25019838"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102859","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102859"}}